Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 248

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response

Montesion, Meagan, Murugesan, Karthikeyan, Jin, Dexter X., Sharaf, Radwa, Sanchez, Nora, Guria, Ameet, Minker, Max, Li, Gerald, Fisher, Virginia, Sokol, Ethan S., Pavlick, Dean C., Moore, Jay A., Braly, Alan, Singal, Gaurav, Fabrizio, David, Comment, Leah A., Rizvi, Naiyer A., Alexander, Brian M., Frampton, Garrett M., Hegde, Priti S., Albacker, Lee A. · 2021 · Cancer Discovery

Abstract

Neoantigen presentation arises as a result of tumor-specific mutations and is a critical component of immune surveillance that can be abrogated by somatic LOH of the human leukocyte antigen class I (HLA-I) locus. To understand the role of HLA-I LOH in oncogenesis and treatment, we utilized a pan-cancer genomic dataset of 83,644 patient samples, a small subset of which had treatment outcomes with immune checkpoint inhibitors (ICI). HLA-I LOH was common (17%) and unexpectedly had a nonlinear relationship with tumor mutational burden (TMB). HLA-I LOH was frequent at intermediate TMB, yet prevalence decreased above 30 mutations/megabase, suggesting highly mutated tumors require alternate immune evasion mechanisms. In ICI-treated patients with nonsquamous non–small cell lung cancer, HLA-I LOH was a significant negative predictor of overall survival. Survival prediction improved when combined with TMB, suggesting TMB with HLA-I LOH may better identify patients likely to benefit from ICIs. Significance: This work shows the pan-cancer landscape of HLA-I LOH, revealing an unexpected “Goldilocks” relationship between HLA-I LOH and TMB, and demonstrates HLA-I LOH as a significant negative predictor of outcomes after ICI treatment. These data informed a combined predictor of outcomes after ICI and have implications for tumor vaccine development. This article is highlighted in the In This Issue feature, p. 211

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-20-0672

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 248

Metadata

Authors
Montesion, M., Murugesan, K., Jin, D. X., Sharaf, R., Sanchez, N., Guria, A., Minker, M., Li, G., Fisher, V., Sokol, E. S., Pavlick, D. C., Moore, J. A., Braly, A., Singal, G., Fabrizio, D., Comment, L. A., Rizvi, N. A., Alexander, B. M., Frampton, G. M., Hegde, P. S., & Albacker, L. A.
Venue
Cancer Discovery
Published
2021-02-01
Volume
11
Issue
2
Pages
282-292
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3096956635
Cited by
248
References
11
FWCI
10.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.